Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’
March 3, 2022 – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, received two CMO Leadership Awards in the categories Expertise and Service for Big Pharma.
“We are extremely pleased to be recognized by our partners. Aji Bio-Pharma has continued to invest in new technologies, quality systems, and, most importantly, our people to increase our capabilities and capacities to meet the needs of our valued clients. In doing so, we further contribute to improving and extending the lives of patients with the drugs we produce.” said Nobu Shimba, CEO, Ajinomoto Bio-Pharma Services US.
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners. The awards are presented by Life Science Leader magazine and Industry Standard Research (ISR). The winning CMOs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services. More than 86 contract manufactures were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Based on ratings of recent outsourced projects provided by sponsors, this experiential feedback is analyzed by sponsor company size to reveal leading CMOs in different performance categories.
Mark Cassidy, CEO, Ajinomoto Bio-Pharma Services EU, stated, “This award is especially meaningful for us as we take great pride in providing personalized service and the expertise to meet our clients’ needs in delivering quality products. For the last 30 years, some of the largest bio-pharma companies have entrusted us to supply product for billions of doses of life saving medicines and thereby realize our mission to help improve the health of humankind.”
“For nearly a decade, these awards have proven most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing.” Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
아지노모토 바이오-파마 서비스(Ajinomoto Bio-Pharma Services)
소개 아지노모토 바이오-파마 서비스는 벨기에, 미국, 일본, 인도에 사업장을 둔 완전 통합형 계약 개발 및 제조 기관(CDMO)으로, 소분자 및 대분자 원료의약품(API)과 중간체에 대한 포괄적인 개발, cGMP 제조, 무균 충전 및 포장 서비스를 제공합니다. 아지노모토 바이오-파마 서비스는 Corynex® 단백질 발현 기술, 올리고뉴클레오티드 합성, 항체-약물 접합체(ADC), 고활성 원료의약품(HPAPI), 생체촉매, 연속 흐름 제조 등을 포함하여, 전임상 및 파일럿 프로그램부터 상용 생산량에 이르기까지 광범위한 혁신적인 플랫폼과 역량을 제공합니다. 아지노모토 바이오-파마 서비스는 고객의 요구를 충족시키기 위해 높은 수준의 품질과 서비스를 제공하는 데 전념하고 있습니다. 자세히 알아보기: www.AjiBio-Pharma.com
